At the World Federation of Hemophilia World Congress, Spark Therapeutics and Pfizer Diagnostics announced factor IX gene transfer vector SPK-9001 success rates in 15 hemophilia B participants. Click or tap here for their press release.
At the World Federation of Hemophilia World Congress, Spark Therapeutics and Pfizer Diagnostics announced factor IX gene transfer vector SPK-9001 success rates in 15 hemophilia B participants. Click or tap here for their press release.
